Sep 17, 2020 8:02am EDT Intensity Therapeutics Doses First Patient with Combination of INT230-6 and Bristol Myers Squibb’s Yervoy® in a Phase 2 Study
Sep 09, 2020 8:02am EDT Intensity Therapeutics Doses First Patients with Combination of INT230-6 and Merck’s Keytruda® in Phase 2 Studies
Jun 25, 2020 7:36am EDT Intensity Therapeutics Announces Publication of Research Reporting that Intratumoral Administration of INT230-6 Demonstrates Tissue Dispersive Properties, Tumor Regression and Elicits Systemic Adaptive Immunity
May 20, 2020 7:35am EDT Intensity Therapeutics’ Abstract (#3016) Selected for Oral Presentation as Part of a Poster Discussion Session at ASCO 2020
Apr 14, 2020 7:35am EDT Intensity Therapeutics Signs Clinical Collaboration Agreement with Bristol Myers Squibb for Advanced Solid Tumors
Mar 30, 2020 7:35am EDT Intensity Therapeutics Reports Safety Results from First Cohort of the KEYNOTE A10 Combination Clinical Trial of INT230-6 and Keytruda®
Nov 07, 2019 7:35am EST Data From Intensity Therapeutics’ Phase 1/2 Study of INT230-6 Highlight Prolonged Disease Control, Abscopal Effects and Immune Response Activity in Patients With Advanced Solid Tumors
Oct 31, 2019 7:35am EDT Intensity Therapeutics Treats First Patient with Combination of INT230-6 and Merck’s Keytruda®
Oct 22, 2019 7:35am EDT Intensity Therapeutics’ Intratumoral INT230-6 Tumor Regression and Immune Response Activity Data Selected for Oral Presentation at SITC 2019 Conference
